Clinical Trial: Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07398950) titled 'Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)' on July 03, 2025.

Brief Summary: The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in adults with heart failure. Model performance will be validated through comparison with technetium-99m pyrophosphate (PYP) imaging results.

Study Start Date: March, 2026

Study Type: OBSERVATIONAL

Condition: ATTR Amyloidosis With Cardiomyopathy Heart Fail...